

Supplementary Table S1. Initial Search Strategies**Search 1: PubMed, search through April 28, 2021 (n= 1031)**

Search 1: (((selen*[Title/Abstract]) OR selenium [Title/Abstract]) OR selenium [MeSH Terms])) AND (((((liver [Title/Abstract]) OR hepat*[Title/Abstract]) OR liver diseases [Title/Abstract]) OR liver [MeSH Terms])) AND (((((((epidemiology [Title/Abstract]) OR epidemiology*[MeSH Terms]) OR mortality* [Title/Abstract]) OR mortality*[MeSH Terms]) OR morbidity* [Title/Abstract]) OR morbidity[MeSH Terms]) OR incidence* [Title/Abstract]) OR incidence [MeSH Terms]))

Search 2: Embase, search through April 28, 2021 (n= 1154)

((('selenium':ab,ti) OR (selen*:ab,ti) OR ('selenium':exp)) AND (('liver':ab,ti) OR (hepat*:ab,ti) OR ('liver diseases':ab,ti) OR ('liver':exp)))
AND ((('epidemiology':ab,ti) OR (mortality:ab,ti) OR ('epidemiology':exp)) AND ((('morbidity':ab,ti) AND ('incidence':ab,ti)

Search 3: Cochrane Library, search through April 28, 2021 (n= 34)

((selenium):ti,ab,kw) OR ((selen*):ti,ab,kw) OR ([selenium] explode all trees)) AND (((liver):ti,ab,kw) OR ((liver diseases):ti,ab,kw) OR

((hepat*):ti,ab,kw) OR (([liver] explode all trees))) OR ((([epidemiology] explode all trees) OR ([mortality] explode all trees) OR ([morbidity] explode all trees)) AND ([[incidence] explode all trees) OR ((epidemiology):ti,ab,kw) OR ((mortality):ti,ab,kw) OR (morbidity):ti,ab,kw)) OR (incidence):ti,ab,kw))

Search 4: Web of science, search through April 28, 2021 (n= 4)

((selen*) AND ((liver diseases OR (disease, liver) OR (hepat*) AND (epidemiology*) OR (mortality*) OR (morbidity*) OR (incidence*)))

Supplementary Table S2. Characteristics of studies included in the meta-analysis

Study; Age group	Continent	Study Design	Sample Source	Case, n	Liver Progression	Mean ± SD	Control, n	Mean ± SD	Quality Score (NOS)
Shamberge 1973; Adult	USA	Case-control	Blood	14	Liver cancer	$150 \pm 26.3 \mu\text{g/L}$	48	$229 \pm 35.2 \mu\text{g/L}$	Serious (9)
				6	Other cirrhosis	$136 \pm 24.2 \mu\text{g/L}$			
				3	Other hepatitis	$145 \pm 16.8 \mu\text{g/L}$			
Burch 1978; Adult	USA	Case-control	Serum	8	Other cirrhosis	$100 \pm 9 \mu\text{g/L}$	13	$120 \pm 6 \mu\text{g/L}$	Serious (9)
Sullivan 1979; Adult	USA	Case-control	Serum	14	Other cirrhosis	$90 \pm 20 \mu\text{g/L}$	37	$120 \pm 10 \mu\text{g/L}$	Serious (9)
Aaseth 1980 ; Adult	Europe	Case-control	Serum	11	Alcoholic cirrhosis	$50.5 \pm 15.8 \mu\text{g/L}^1$	40	$121 \pm 19.7 \mu\text{g/L}^1$	Serious (8)
Aaseth 1982; Adult	Europe	Case-control	Serum	11	Alcoholic cirrhosis	$95.6 \pm 38.7 \mu\text{g/L}^1$	40	$121 \pm 19.7 \mu\text{g/L}^1$	Serious (9)
				12	Primary cirrhosis	$108 \pm 15.0 \mu\text{g/L}^1$			
				12	Other cirrhosis	$96.3 \pm 21.3 \mu\text{g/L}^1$			
				15	Viral hepatitis	$88.4 \pm 21.3 \mu\text{g/L}^1 (\text{HBV})$			
				4	Viral hepatitis	$94.8 \pm 40.3 \mu\text{g/L}^1 (\text{HCV})$			
Välimäki 1983; Adult	Europe	Case-control	Serum	13	Alcoholic cirrhosis	$43.3 \pm 13.4 \mu\text{g/L}$	45	$83.1 \pm 15.7 \mu\text{g/L}$	Serious (9)
				17	Primary cirrhosis	$47.3 \pm 7.9 \mu\text{g/L}$			
Korpela 1985; Adult	Europe	Case-control	Serum	11	Alcoholic fatty liver disease	$55.8 \pm 21.2 \mu\text{g/L}$	25	$88.7 \pm 11.0 \mu\text{g/L}$	Serious (9)
				6	Alcoholic hepatitis	$46.0 \pm 14.1 \mu\text{g/L}$			
				22	Alcoholic cirrhosis	$41.1 \pm 12.8 \mu\text{g/L}$			

Milman 1986; Adult	Europe	Case-control	Liver	14	Alcoholic cirrhosis	$316 \pm 158 \mu\text{g/kg}^1$	74	$2210 \pm 395 \mu\text{g/kg}^1$	Serious (9)
				13	Primary cirrhosis	$8690 \pm 474 \mu\text{g/kg}^1$			
Sharda 1986; Children	Asia	Case-control	Liver	20	Other cirrhosis	$160 \pm 10 \mu\text{g/kg}^1$	20	$100 \pm 10 \mu\text{g/kg}^1$	Serious (9)
			Hair	20	Other cirrhosis	$400 \pm 80 \mu\text{g/kg}^1$	20	$500 \pm 60 \mu\text{g/kg}^1$	
			Nail	20	Other cirrhosis	$1000 \pm 40 \mu\text{g/kg}^1$	20	$700 \pm 50 \mu\text{g/kg}^1$	
Johansson 1986; Adult	Europe	Case-control	Plasma	21	Alcoholic cirrhosis	$58.4 \pm 11.1 \mu\text{g/L}^1$	16	$79.8 \pm 11.1 \mu\text{g/L}^1$	Serious (1)
			Blood	21	Alcoholic cirrhosis	$68.7 \pm 12.6 \mu\text{g/L}^1$	16	$94.0 \pm 18.2 \mu\text{g/L}^1$	
			Plasma	15	Alcoholic hepatitis	$78.2 \pm 19.7 \mu\text{g/L}^1$	16	$79.8 \pm 11.1 \mu\text{g/L}^1$	
Corrocher 1986; Adult	Europe	Case-control	Serum	12	Liver cancer	$84.5 \pm 32.4 \mu\text{g/L}^1$	8	$126.4 \pm 8.7 \mu\text{g/L}^1$	Serious (9)
Dworkin 1988; Adult	USA	Case-control	liver	12	Alcoholic cirrhosis	$731 \pm 77 \mu\text{g/kg}^1$	13	$1310 \pm 166 \mu\text{g/kg}^1$	Serious (8)
Casaril 1989; Adult	Europe	Case-control	Serum	55	Other cirrhosis	$45.0 \pm 15.8 \mu\text{g/L}^1$	47	$72.7 \pm 12.6 \mu\text{g/L}^1$	Serious (9)
Välimäki 1991; Adult	Europe	Case-control	Blood	8	Primary cirrhosis	$288 \pm 15.0 \mu\text{g/L}^1$	8	$318 \pm 17.4 \mu\text{g/L}^1$	Serious (9)
Ward 1992; Adult	Europe	Case-control	Plasma	11	Alcoholic fatty liver disease	$77.4 \pm 49.0 \mu\text{g/L}^1$	10	$109.9 \pm 34.0 \mu\text{g/L}^1$	Serious (7)
				5	Alcoholic cirrhosis	$62.4 \pm 29.2 \mu\text{g/L}^1$ (P-Ch A-B)			
				4	Alcoholic cirrhosis	$61.6 \pm 16.6 \mu\text{g/L}^1$ P-Ch C)			
Thuluvath 1992; Adult	Europe	Case-control	Serum	51	Alcoholic cirrhosis	$63.6 \pm 18.2 \mu\text{g/L}$	56	$87.8 \pm 21.1 \mu\text{g/L}$	Serious (9)
				45	Primary cirrhosis	$60.6 \pm 13.6 \mu\text{g/L}$			
				8	Other cirrhosis	$59.3 \pm 13.3 \mu\text{g/L}$			

				19	Other hepatitis	$73.9 \pm 20.3 \mu\text{g/L}$				
				9	Viral hepatitis	$65.4 \pm 19.0 \mu\text{g/L}$				
				17	Liver cancer	$76.8 \pm 18.3 \mu\text{g/L}$				
Gerli 1992; Adult	Europe	Case-control	Serum	21	Alcoholic hepatitis	$67.1 \pm 18.2 \mu\text{g/L}^1$ (50	$75.0 \pm 15.0 \mu\text{g/L}^1$	Serious (9)	
				22	Alcoholic cirrhosis	$67.1 \pm 15.8 \mu\text{g/L}^1$ (P-Ch A)				
				30	Alcoholic cirrhosis	$56.1 \pm 19.7 \mu\text{g/L}^1$ (P-Ch B)				
				21	Alcoholic cirrhosis	$48.2 \pm 10.3 \mu\text{g/L}^1$ (P-Ch C)				
Buljevac 1996; Adult	Europe	Case-control	Serum	49	Liver cirrhosis	$39.0 \pm 14.0 \mu\text{g/L}^1$	202	$66.8 \pm 9.13 \mu\text{g/L}^1$	Serious (7)	
				10	Liver cancer	$42.0 \pm 10.6 \mu\text{g/L}^1$				
Loguercio 1997; Adult	Europe	Case-control	Plasma	8	Viral hepatitis	$120 \pm 30 \mu\text{g/L}^1$	10	$100 \pm 10 \mu\text{g/L}$	Moderate (6)	
				18	Primary cirrhosis	$70 \pm 10 \mu\text{g/L}^1$ malnourished				
				18	Primary cirrhosis	$70 \pm 10 \mu\text{g/L}^1$ malnourished				
			Blood	8	Viral hepatitis	$140 \pm 20 \mu\text{g/L}^1$				
				18	Primary cirrhosis	$100 \pm 10 \mu\text{g/L}^1$ malnourished	10	$180 \pm 30 \mu\text{g/L}^1$		
				14	Primary cirrhosis	$90 \pm 10 \mu\text{g/L}^1$ Well-nourished				
Guarini 1998; Adult	Europe	Case-control	Serum	20	Alcoholic cirrhosis	$75.0 \pm 15.0 \mu\text{g/L}^1$	40	$94.0 \pm 15.8 \mu\text{g/L}^1$	Serious (9)	
Yu 1999; Adult	Asia	Cohort study	Plasma	13	Other cirrhosis	$75.8 \pm 27.6 \mu\text{g/L}^1$				
				139	Viral hepatitis	$145 \pm 37.6 \mu\text{g/L}$	138	$151 \pm 35.2 \mu\text{g/L}$	Serious (9)	
				69	Liver cancer	$132 \pm 30.9 \mu\text{g/L}$				

Navarro-Alarcón 2002; Adult	Europe	Cross-section	Serum	12 38	Other cirrhosis Viral hepatitis	$41.0 \pm 12.4 \mu\text{g/L}$ $52.4 \pm 15.6 \mu\text{g/L}$	130	$74.9 \pm 27.3 \mu\text{g/L}$	Serious ³ (7)	
Chin-Thin 2002; Adult	Asia	Case-control	Blood	51	Liver cancer	$180 \pm 20 \mu\text{g/L}^1$	50	$280 \pm 60 \mu\text{g/L}^1$	Serious (9)	
Czucejko 2003; Adult	Europe	Case-control	Blood	23	Viral hepatitis	$58.6 \pm 13.3 \mu\text{g/L}^1 (\text{ALT} \leq 40 \text{ U/L})$	50	$89.5 \pm 15.6 \mu\text{g/L}^1$	Serious (9)	
				36	Viral hepatitis	$74.3 \pm 15.0 \mu\text{g/L}^1 (\text{ALT} \geq 40 \text{ U/L})$				
			Plasma	23	Viral hepatitis	$43.6 \pm 12.1 \mu\text{g/L}^1 (\text{ALT} \leq 40 \text{ U/L})$	50	$67.4 \pm 11.7 \mu\text{g/L}^1$		
				36	Viral hepatitis	$53.7 \pm 11.6 \mu\text{g/L}^1 (\text{ALT} \geq 40 \text{ U/L})$				
			Blood	26	Other cirrhosis	$52.5 \pm 15.7 \mu\text{g/L}^1 (\text{ALT} \leq 40 \text{ U/L})$	50	$89.5 \pm 15.6 \mu\text{g/L}^1$		
				38	Other cirrhosis	$64.4 \pm 17.5 \mu\text{g/L}^1 (\text{ALT} \geq 40 \text{ U/L})$				
			Plasma	26	Other cirrhosis	$37.4 \pm 11.6 \mu\text{g/L}^1 (\text{ALT} \leq 40 \text{ U/L})$	50	$67.4 \pm 11.7 \mu\text{g/L}^1$		
				38	Other cirrhosis	$48.7 \pm 15.0 \mu\text{g/L}^1 (\text{ALT} \geq 40 \text{ U/L})$				
Sakoda 2005; Adult	Asia	Nest case control	Nail	166	Liver cancer	$3.1 \pm 1.5 \text{ ppm}$	394	$3.5 \pm 0.45 \text{ ppm}$	Serious (10)	
Pemberton 2005; Adult	Europe	Case-control	Serum	24	Alcoholic cirrhosis	$46.2 \pm 7.2 \mu\text{g/L}^1$	49	$101 \pm 3.28 \mu\text{g/L}^1$	Serious (9)	
Ko 2005; Adult	Asia	Cohort study	Plasma	33	Viral hepatitis	$159 \pm 5.3 \mu\text{g/L}$	31	$217 \pm 7.44 \mu\text{g/L}$	Serious	

			Blood	33	Viral hepatitis	$55.1 \pm 3.79 \mu\text{g/L}$	31	$139 \pm 5.76 \mu\text{g/L}$	(9)
Sayed 2005; Adult	Africa	Cross-section	Blood	25	Viral hepatitis	$154 \pm 12.8 \mu\text{g/L}^1$ (HBsAg positive)	41	$166 \pm 23.5 \mu\text{g/L}^1$	Serious ³ (8)
				12	Viral hepatitis	$154 \pm 12.1 \mu\text{g/L}^1$ (Anti-HCV Ab positive)			
				6	Viral hepatitis	$158 \pm 6.6 \mu\text{g/L}^1$ (Combined infection)			
Lin 2006; Adult	Asia	Case-control	Blood	40	Viral hepatitis	$124 \pm 20.4 \mu\text{g/L}$ (HBV carriers)	50	$129 \pm 21.5 \mu\text{g/L}$	Serious (8)
				50	Viral hepatitis	$124 \pm 22.6 \mu\text{g/L}$ (HBV)			
				18	Liver cancer	$109 \pm 21.8 \mu\text{g/L}$			
				20	Other cirrhosis	$118 \pm 25.3 \mu\text{g/L}$			
Váli 2008; Adult	Europe	Case-control	Blood	11	Liver cancer	$314 \pm 83.7 \mu\text{g/kg}$ (Benign)	30	$301 \pm 57.2 \mu\text{g/kg}$	Serious (8)
				23	Liver cancer	$129 \pm 58.3 \mu\text{g/kg}$ (HCC)			
González-Reimers 2009; Adult	Europe	Case-control	Serum	9	Viral hepatitis	$81.3 \pm 10.1 \mu\text{g/L}$ (HCV)	20	$82.1 \pm 9.1 \mu\text{g/L}$	Serious (9)
				12	Viral hepatitis	$73.4 \pm 14.5 \mu\text{g/L}$ (HCV patient drink)			
				19	Alcoholic hepatitis	$70.0 \pm 14.0 \mu\text{g/L}$			
Balamtekin 2010; children	Asia	RCT	Plasma	35	Viral hepatitis	$18.4 \pm 9.06 \mu\text{g/L}^1$	27	$44.7 \pm 10.2 \mu\text{g/L}^1$	Serious ² (9)
Martínez-Peinado 2010; Adult	Europe	Case-control	Blood	93	Other cirrhosis	$56.9 \pm 18.9 \mu\text{g/L}^1$	30	$73.1 \pm 19.0 \mu\text{g/L}^1$	Serious (9)
Uslu 2010; children	Asia	Case-control	Serum	38	Other cirrhosis	$42.4 \pm 8.2 \mu\text{g/L}$	41	$64.4 \pm 16.9 \mu\text{g/L}$	Serious (7)

Himoto 2011; adult	Asia	Case-control	Serum	10	Viral hepatitis	$125 \pm 24 \mu\text{g/L}^1$ (HCV F3)	11	$148 \pm 16 \mu\text{g/L}^1$	Serious (9)	
				10	Viral hepatitis	$113 \pm 13 \mu\text{g/L}^1$ (HCV F4)				
Khan 2012; Adult	Asia	Case-control	Blood	5	Viral hepatitis	$138 \pm 0.36 \mu\text{g/L}$ (HBV female)	10	$199 \pm 104 \mu\text{g/L}$	Serious (9)	
				36	Viral hepatitis	$77.4 \pm 0.47 \mu\text{g/L}$ (HBV male)				
				38	Viral hepatitis	$107.5 \pm 0.44 \mu\text{g/L}$ (HCV female)	16	$214 \pm 164 \mu\text{g/L}$		
				71	Viral hepatitis	$101.6 \pm 0.55 \mu\text{g/L}$ (HCV male)				
Kolachi 2012; Adult	Asia	RCT	Hair	26	Other cirrhosis	$680 \pm 310 \mu\text{g/kg}^1$ (20-45 years old)	43	$1280 \pm 250 \mu\text{g/kg}^1$	Serious ² (4)	
				52	Liver cancer	$660 \pm 140 \mu\text{g/kg}^1$ (20-45 years old)				
				14	Other cirrhosis	$710 \pm 410 \mu\text{g/kg}^1$ (46-60 years old)	32	$1290 \pm 430 \mu\text{g/kg}^1$		
				40	Liver cancer	$690 \pm 380 \mu\text{g/kg}^1$ (46-60 years old)				
			Serum	26	Other cirrhosis	$48.5 \pm 6.90 \mu\text{g/L}$ (20-45 years old)	43	$69.6 \pm 11.2 \mu\text{g/L}$		
				52	Liver cancer	$44.8 \pm 2.84 \mu\text{g/L}$ (20-45 years old)				
				14	Other cirrhosis	$45.8 \pm 8.90 \mu\text{g/L}$ (46-60 years old)	32	$75.7 \pm 8.90 \mu\text{g/L}$		
				40	Liver cancer	$43.1 \pm 3.85 \mu\text{g/L}$ (46-60 years old)				

						years old)				
			Blood	26	Other cirrhosis	$114 \pm 6.32 \text{ } \mu\text{g/L}$ (20-45 years old)	43	$175 \pm 7.41 \text{ } \mu\text{g/L}$		
				52	Liver cancer	$104 \pm 7.83 \text{ } \mu\text{g/L}$ (20-45 years old)				
				14	Other cirrhosis	$99.8 \pm 10.2 \text{ } \mu\text{g/L}$ (46-60 years old)	32	$163 \pm 7.82 \text{ } \mu\text{g/L}$		
				40	Liver cancer	$97.7 \pm 6.38 \text{ } \mu\text{g/L}$ (46-60 years old)				
Kazi 2012; adult	Asia	RCT	Serum	31	Liver cancer	$36.2 \pm 3.95 \text{ } \mu\text{g/L}$	120	$77.0 \pm 13.5 \text{ } \mu\text{g/L}$	Serious ² (4)	
				41	Other cirrhosis	$41.8 \pm 12.5 \text{ } \mu\text{g/L}$				
			Blood	31	Liver cancer	$63.5 \pm 9.22 \text{ } \mu\text{g/L}$	120	$180 \pm 6.83 \text{ } \mu\text{g/L}$		
				41	Other cirrhosis	$112 \pm 8.97 \text{ } \mu\text{g/L}$				
Bettinger 2013; Adult	Europe	Case-control	Plasma	12	Viral hepatitis	$84.7 \pm 16.4 \text{ } \mu\text{g/L}$	10	$118 \pm 15.7 \text{ } \mu\text{g/L}$	Serious (9)	
				10	Liver cancer	$85 \pm 11.5 \text{ } \mu\text{g/L}$				
				10	Other cirrhosis	$99.8 \pm 11 \text{ } \mu\text{g/L}$				
Pan 2013; Adult	Asia	Case-control	Hair	15	Alcoholic hepatitis	$450 \pm 130 \text{ } \mu\text{g/kg}^1$ (15-25 years old)	18	$680 \pm 180 \text{ } \mu\text{g/kg}^1$	Serious (9)	
				12	Simple fatty liver disease	$560 \pm 170 \text{ } \mu\text{g/kg}^1$ (15-25 years old)				
				30	Alcoholic hepatitis	$470 \pm 130 \text{ } \mu\text{g/kg}^1$ (26-35 years old)	34	$620 \pm 160 \text{ } \mu\text{g/kg}^1$		
				18	Simple fatty liver disease	$560 \pm 140 \text{ } \mu\text{g/kg}^1$ (26-35 years old)				

				18	Alcoholic hepatitis	$310 \pm 90 \text{ } \mu\text{g/kg}^1$ (36-45 years old)			
				6	Simple fatty liver disease	$420 \pm 110 \text{ } \mu\text{g/kg}^1$ (36-45 years old)			
				15	Alcoholic hepatitis	$340 \pm 80 \text{ } \mu\text{g/kg}^1$ (46-55 years old)			
				4	Simple fatty liver disease	$390 \pm 70 \text{ } \mu\text{g/kg}^1$ (46-55 years old)			
Kolachi 2013; Adult	Asia	RCT	Blood	132	Viral hepatitis	$107 \pm 5.56 \text{ } \mu\text{g/L}$ (Certified Value)	128	$172 \pm 5.43 \text{ } \mu\text{g/L}$	Serious ² (4)
			Serum	132	Viral hepatitis	$51.6 \pm 2.66 \text{ } \mu\text{g/L}$ (Measured Value)	128	$68.4 \pm 6.12 \text{ } \mu\text{g/L}$	
Nangliya 2015; Adult	Asia	Cross-section	Serum	150	Other cirrhosis	$70.8 \pm 15.3 \text{ } \mu\text{g/L}^1$	50	$124.7 \pm 16.6 \text{ } \mu\text{g/L}^1$	Serious ³ (7)
Hughes 2016; Adult	Europe	Cohort study	Blood	40	Liver cancer	$82.3 \pm 18.3 \text{ } \mu\text{g/L}$ (HCC)	40	$87.5 \pm 15.1 \text{ } \mu\text{g/L}$	Serious (9)
				100	Liver cancer	$82.1 \pm 8.17 \text{ } \mu\text{g/L}$ (GBTC)	100	$85.9 \pm 9.77 \text{ } \mu\text{g/L}$	
				121	Liver cancer	$71.3 \pm 5.77 \text{ } \mu\text{g/L}$ (IHBC)	121	$85.2 \pm 10.4 \text{ } \mu\text{g/L}$	
Yang 2016; Adult	Asia	Cross-section	Blood	3732	NAFLD	$270 \pm 5.35 \text{ } \mu\text{g/L}$	5118	$192 \pm 3.60 \text{ } \mu\text{g/L}$	Serious ³ (8)
Prystupa 2017; Adult	Europe	case-control	Blood	29	Alcoholic cirrhosis	$68 \pm 14 \text{ } \mu\text{g/L}^1$ (P-Ch A)	20	$100 \pm 13 \text{ } \mu\text{g/L}^1$	Serious (9)
				36	Alcoholic cirrhosis	$85 \pm 16 \text{ } \mu\text{g/L}^1$ (P-Ch B)			
				34	Alcoholic cirrhosis	$72 \pm 17 \text{ } \mu\text{g/L}^1$ (P-Ch C)			
Dhanda 2020; Adult	Europe	Cohort study	Serum	302	Alcoholic hepatitis	$47.4 \pm 23.7 \text{ } \mu\text{g/L}^1$	15	$103 \pm 15.8 \text{ } \mu\text{g/L}^1$	Serious (9)
				11	Other cirrhosis	$63.2 \pm 31.6 \text{ } \mu\text{g/L}^1$			

Fu 2020; Adult	Asia	Case-control	Serum	105	Liver cancer	$88.3 \pm 20.6 \mu\text{g/L}$	105	$167 \pm 38.9 \mu\text{g/L}$	Serious (9)
Li 2020; Adult	Asia	Cross-section	Blood	144	NAFLD	$157 \pm 6.95 \mu\text{g/L}$ (from Longitudinal analysis)	522	$159 \pm 8.33 \mu\text{g/L}$	Serious ³ (7)
				330	NAFLD	$157 \pm 8.04 \mu\text{g/L}$ (from Cross-sectional analysis)	1264	$156 \pm 7.69 \mu\text{g/L}$	
Wang 2021; Adult	USA	Cross-section	Serum	1319	NAFLD	$129 \pm 40.0 \mu\text{g/L}$	2508	$127 \pm 40.0 \mu\text{g/L}$	Serious ³ (8)

NAFLD: non-alcoholic fatty liver, HBV: hepatitis B virus, HCV: hepatitis C virus, SD: standard deviation, HCC: Hepatocellular carcinoma ; GBTC: Biliary tract cancer, IHBC:Intrahepatic bile duct cancer, P-Ch: Child-Pugh , ALT: alanine transaminase,

¹ the data were converted to $\mu\text{g/L}$ or $\mu\text{g/kg}$ for consistency.

² the quality score measured by Jadad scale, the score ≥ 4 means that the quality of this study is serious

³ the quality score measured by AHRQ scale, the score ≥ 7 means that the quality of this study is serious